Ligand Pharmaceuticals INC (LGND) Shares Rose While Conestoga Capital Advisors LLC Has Raised by $6.49 Million Its Stake

September 16, 2018 - By Matthew Richard

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) LogoInvestors sentiment increased to 1.11 in 2018 Q2. Its up 0.05, from 1.06 in 2018Q1. It improved, as 16 investors sold LGND shares while 109 reduced holdings. 42 funds opened positions while 97 raised stakes. 22.99 million shares or 1.94% more from 22.56 million shares in 2018Q1 were reported. Verity Asset Inc accumulated 2,034 shares. Ellington Management Gp Ltd Liability Co reported 0.06% stake. Hood River Cap Ltd Liability Co accumulated 211,152 shares. Jpmorgan Chase And holds 8,970 shares or 0% of its portfolio. Us National Bank De holds 11,130 shares. Nomura stated it has 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Marshall Wace Ltd Liability Partnership accumulated 5,662 shares. First Advsr Lp invested in 0.01% or 22,760 shares. Congress Asset Ma holds 0.06% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 21,845 shares. Fifth Third State Bank invested in 0% or 3,039 shares. Mutual Of America Mgmt Limited Liability Co holds 0% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 78 shares. 2,120 are held by Smith Asset Gru Limited Partnership. Avalon Ltd accumulated 0.08% or 12,770 shares. Prudential has 78,916 shares. Kopp Invest Ltd Liability Corporation owns 21,405 shares for 3.59% of their portfolio.

Since April 2, 2018, it had 0 buys, and 15 insider sales for $48.59 million activity. The insider HIGGINS JOHN L sold 12,405 shares worth $2.23 million. $1.49 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by FOEHR MATTHEW W. On Monday, June 4 LAMATTINA JOHN L sold $778,039 worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) or 4,000 shares. $4.71 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was sold by Korenberg Matthew E on Wednesday, August 29. Patel Sunil sold $10.15 million worth of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Thursday, August 16. 27,942 shares were sold by Aryeh Jason, worth $6.76 million.

Conestoga Capital Advisors Llc increased its stake in Ligand Pharmaceuticals Inc (LGND) by 6.67% based on its latest 2018Q2 regulatory filing with the SEC. Conestoga Capital Advisors Llc bought 31,364 shares as the company’s stock rose 38.65% with the market. The institutional investor held 501,894 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $103.98 million, up from 470,530 at the end of the previous reported quarter. Conestoga Capital Advisors Llc who had been investing in Ligand Pharmaceuticals Inc for a number of months, seems to be bullish on the $5.38 billion market cap company. The stock decreased 0.41% or $1.05 during the last trading session, reaching $254.79. About 324,368 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 86.03% since September 16, 2017 and is uptrending. It has outperformed by 70.41% the S&P500.

More important recent Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) news were published by: which released: “3 Top Biotech Stocks to Buy in September” on September 07, 2018, also published article titled: “Ligand: My Favorite Biotech Stock”, published: “SEC charges Ligand Pharma short seller with “short and distort” scheme” on September 12, 2018. More interesting news about Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was released by: and their article: “3 Monster Biotech Stocks in the Making” with publication date: September 05, 2018.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Ratings Coverage

Among 4 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Ligand Pharmaceuticals has $260 highest and $23000 lowest target. $248.67’s average target is -2.40% below currents $254.79 stock price. Ligand Pharmaceuticals had 4 analyst reports since June 21, 2018 according to SRatingsIntel. The firm has “Neutral” rating by Roth Capital given on Wednesday, August 8. Craig Hallum maintained the shares of LGND in report on Wednesday, June 27 with “Buy” rating.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.